Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
scPharmaceuticals (SCPH) Stock Price & Analysis
404 Followers
SCPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.24 - $8.78
Previous Close$4.73
Volume174.72K
Average Volume (3M)228.44K
Market Cap
$170.54M
Enterprise Value$152.94M
Total Cash (Recent Filing)$58.40M
Total Debt (Recent Filing)$40.80M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 07, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding36,054,409
10 Day Avg. Volume247,802
30 Day Avg. Volume228,438
Standard Deviation0.20
R-Squared0.00031
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)23.81
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.67
Enterprise Value/Gross Profit15.63
Enterprise Value/Ebitda-3.15
Forecast
1Y Price Target
$21.25Price Target Upside349.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
scPharmaceuticals News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
Bulls Say, Bears Say
Bulls Say
Management ConfidenceManagement remains confident in their ability to meet 2024 Furoscix sales consensus of $40MM (+194%).
Prescription DemandThe prescriber base continues to increase and now there are 2,184 unique prescribers of Furoscix, an increase of ~29% from 1,696 in 4Q23.
Sales PerformanceFuroscix sales in 1Q24 were $6.1M, an increase of 196% from 1Q23 which was the first full quarter of launch.
Bears Say
CyberattacksThe Change Healthcare cyberattacks had a ~10% impact on prescriptions filled in the quarter, translating to lost sales of $600K-$700K.
Growth HindranceThe Change Healthcare cyberattack and typical seasonality around payer deductible resets collectively hindered Furoscix’ growth.
Market PressureSCPH stock has been under pressure as investors wait for signs of a more tangible launch inflection for Furoscix in decompensated heart failure (HF).
---
Ownership Overview
71.41% Insiders
8.77% Mutual Funds
6.79% Other Institutional Investors
13.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $3.24 and its highest was $8.78 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
Currently, no data Available
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on May 14, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.437 by $0.077.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -$0.41.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 36,054,410 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.437. Following the earnings report the stock price went up 1.556%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Among the largest hedge funds holding scPharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds scPharmaceuticals Inc’s shares valued at N/A.
---
scPharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.25 (349.26% Upside)
$21.25 (349.26% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.42%
12-Months-Change
Fundamentals
Return on Equity
-114.99%
Trailing 12-Months
Asset Growth
-38.41%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
---
SCPH Earnings Call
Q1 2024
0:00 / 0:00
---
SCPH Stock 12 Month Forecast
Average Price Target
$21.25
▲(349.26% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Bausch Health Companies
―
Karyopharm Therapeutics
―
Seres Therapeutics
―
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-0.83%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -0.83% per trade.
---